Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that 2 adalimumab biosimilars be treated as equivalent to the reference adalimumab, Humira, and be subject to substitution at the pharmacy level.
The products, Amgen’s Amgevita and Samsung Bioepis’ Hadlima, will be “a-flagged,” or given a listing that allows them to be substituted for Humira—or for one another—by a pharmacist for the indications that they share, although the prescribing physician retains the right to prevent substitution by requiring a prescription to be dispensed as written.
Read more about biosimilars in Australia.
In the case of Amgevita, which is approved for all indications of the reference product, a pharmacist could substitute Amgevita for Humira or Hadlima. In the case of Hadlima, which is only approved to treat rheumatoid arthritis (RA), Hadlima could be substituted by the pharmacist for either Humira or Amgevita to treat RA only.
Furthermore, the PBAC recommended that Australia’s “uptake drivers” be applied to adalimumab in the same way that they have been applied to etanercept and infliximab. The uptake drivers are policies that encouraging prescribing of biosimilars over branded drugs for new patients and that provide a faster and simpler preapproval process for patients to receive a biosimilar drug than a branded drug.
As part of the uptake driver process, the Australian government publishes fact sheets on the biosimilars, with separate documents made available to prescribers, pharmacists, and patients or their caregivers.
Australia’s approach to promoting biosimilar uptake through “a-flagging” biosimilars for substitution stands in contrast to the strategies used in the United States and Europe. In the United States, pharmacy-level substitution will only be permissible by law for products that gain the FDA’s designation of interchangeability (final guidance on which is yet to be published), and rules governing substitution will vary among US states according to local laws. In Europe, pharmacy-level substitution is, for the most part, forbidden; Estonia, France, Latvia, Poland, and Russia are notable exceptions.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.